Haleon

Haleon

Haleon was formally created in July 2022 through the demerger of GSK's consumer healthcare division, a transaction that immediately listed the company on the London Stock Exchange and positioned it as the global number one in consumer health by revenue. The founding portfolio comprised joint ventures with Pfizer and Novartis that GSK had previously consolidated, forming a concentrated bet that over-the-counter medicines, vitamins, and oral care products would outperform as a dedicated entity rather than as a subsidiary competing for capital inside a pharmaceutical giant. Strategy and capital deployment centers entirely on the consumer health value chain — developing, marketing, and acquiring non-prescription brands across five categories: oral health, pain relief, respiratory health, digestive health, and vitamins, minerals, and supplements. The firm operates its own manufacturing and distribution networks, with products sold in over 100 countries. The portfolio is structured as a collection of category-leading power brands including Sensodyne, Panadol, Advil, Voltaren, Centrum, Otrivin, and Polident. Geographic exposure splits between North America, EMEA, and Asia-Pacific, with significant positions in markets like China, India, and the United States. Scale reflects the heritage: Haleon reports approximately £11 billion in annual revenue and employs more than 25,000 people across manufacturing plants and commercial operations on every continent. The company maintains its global headquarters in Weybridge, Surrey, alongside a major operational hub in Warren, New Jersey. The corporate structure includes no external fund vehicles, no multi-family office overlay, and no co-investor club — it is a publicly traded, single-entity operating company with a fiduciary obligation to its broad shareholder base. May 2024: Haleon announced the sale of its nicotine replacement therapy business outside the US to Dr. Reddy's Laboratories for £500 million, a portfolio-shaping move to sharpen focus on its core categories (per the firm, May 2024). Structurally, Haleon differs from every other entity in the institutional allocator universe: it is not a family office, not a fund, and not a holding company for financial assets. It is an operating business that controls the physical supply chain from R&D through to retail distribution. For an allocator considering consumer health exposure, Haleon offers liquid equity access to a pure-play portfolio of durable brand assets — something previously unavailable except through diluted exposure inside diversified pharma conglomerates.